1
|
Norton T, Lynn MA, Rossouw C, Abayasingam A, Perkins G, Hissaria P, Bull RA, Lynn DJ. B and T cell responses to the BNT162b2 COVID-19 mRNA vaccine are not impaired in germ-free or antibiotic-treated mice. Gut 2023:gutjnl-2023-329810. [PMID: 37500502 DOI: 10.1136/gutjnl-2023-329810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2023] [Accepted: 07/15/2023] [Indexed: 07/29/2023]
Affiliation(s)
- Todd Norton
- Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Miriam Anne Lynn
- Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Infection and Immunity, Flinders Health and Medical Research Institute, Bedford Park, South Australia, Australia
| | - Charné Rossouw
- Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Infection and Immunity, Flinders Health and Medical Research Institute, Bedford Park, South Australia, Australia
| | - Arunasingam Abayasingam
- The Viral Immunology Systems Program, The Kirby Institute, Sydney, New South Wales, Australia
- School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - Griffith Perkins
- Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
- Immunology Directorate, SA Pathology, Adelaide, South Australia, Australia
| | - Pravin Hissaria
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
- Immunology Directorate, SA Pathology, Adelaide, South Australia, Australia
- Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Rowena Anne Bull
- The Viral Immunology Systems Program, The Kirby Institute, Sydney, New South Wales, Australia
- School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - David John Lynn
- Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Infection and Immunity, Flinders Health and Medical Research Institute, Bedford Park, South Australia, Australia
| |
Collapse
|
2
|
Alouani E, Mercier M, Flecchia C, Auclin E, Hollebecque A, Mazard T, Turpin A, Pernot S, Cohen R, Dutherage M, Kim S, Sclafani F, Ben-Abdelghani M, Herve C, Aparicio T, De La Fouchardière C, Perkins G, Hautefeuille V, Jaffrelot M, Gallois C, Bongard V, Tougeron D, Taïeb J, Guimbaud R. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study. ESMO Open 2023; 8:101574. [PMID: 37244250 DOI: 10.1016/j.esmoop.2023.101574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/23/2023] [Accepted: 04/25/2023] [Indexed: 05/29/2023] Open
Abstract
BACKGROUND Immunotherapy demonstrated remarkable efficacy in metastatic colorectal cancers (mCRCs) with mismatch repair deficiency (MMRd)/microsatellite instability (MSI). However, data regarding efficacy and safety of immunotherapy in the routine clinical practice are scarce. PATIENTS AND METHODS This is a retrospective, multicenter study aiming to evaluate efficacy and safety of immunotherapy in routine clinical practice and to identify predictive markers for long-term benefit. Long-term benefit was defined as progression-free survival (PFS) exceeding 24 months. All patients who received immunotherapy for an MMRd/MSI mCRC were included. Patients who received immunotherapy in combination with another known effective therapeutic class agent (chemotherapy or tailored therapy) were excluded. RESULTS Overall, 284 patients across 19 tertiary cancer centers were included. After a median follow-up of 26.8 months, the median overall survival (mOS) was 65.4 months [95% confidence interval (CI) 53.8 months-not reached (NR)] and the median PFS (mPFS) was 37.9 months (95% CI 30.9 months-NR). There was no difference in terms of efficacy or toxicity between patients treated in the real-world or as part of a clinical trial. Overall, 46.6% of patients had long-term benefit. Independent markers associated with long-term benefit were Eastern Cooperative Oncology Group-performance status (ECOG-PS) 0 (P = 0.025) and absence of peritoneal metastases (P = 0.009). CONCLUSIONS Our study confirms the efficacy and safety of immunotherapy in patients with advanced MMRd/MSI CRC in the routine clinical practice. ECOG-PS score and absence of peritoneal metastases provide simple markers that could help identify patients who benefit the most from this treatment.
Collapse
Affiliation(s)
- E Alouani
- Digestive Oncology Department, Rangueil Hospital, University Hospital of Toulouse, Toulouse.
| | - M Mercier
- University of Poitiers and Gastroenterology and Hepatology Department, Poitiers University Hospital, Poitiers
| | - C Flecchia
- Institut du Cancer Paris CARPEM, Université Paris Cité, Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris, Paris
| | - E Auclin
- Department of Oncology, Hôpital Européen Georges Pompidou, AP-HP Centre, Université Paris Cité, Paris
| | - A Hollebecque
- Drug Development Department (DITEP), Gustave Roussy, Saclay University of Paris, Villejuif
| | - T Mazard
- Institute de Recherche en Cancérologie de Montpellier, INSERM, University of Montpellier, ICM, Montpellier
| | - A Turpin
- Department of Medical Oncology, CNRS UMR9020, Inserm UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CHU Lille, Lille
| | - S Pernot
- Department of Digestive Oncology, Institut Bergonié, Bordeaux
| | - R Cohen
- Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris
| | - M Dutherage
- Department of Medical Oncology, Henri Becquerel Centre, Rouen
| | - S Kim
- Department of Medical Oncology, University Hospital of Besançon, Besançon, France
| | - F Sclafani
- Department of Digestive Oncology, The Brussels University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | | | - C Herve
- Clinique Mutualiste de Grenoble, Institut de cancérologie Daniel Hollard, Grenoble
| | - T Aparicio
- Gastroenterology Department, Saint Louis Hospital, Paris
| | | | - G Perkins
- Department of Gastroenterology, University Hospital Pontchaillou, Rennes
| | - V Hautefeuille
- Department of Hepato-Gastroenterology and Digestive Oncology, CHU Amiens Picardie, Amiens
| | - M Jaffrelot
- Digestive Oncology Department, Rangueil Hospital, University Hospital of Toulouse, Toulouse
| | - C Gallois
- Institut du Cancer Paris CARPEM, Université Paris Cité, Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris, Paris
| | - V Bongard
- Epidemiology Department CHU de Toulouse, UMR 1295, Centre d'Epidémiologie et de Recherche en santé des Populations, Université Paul Sabatier Toulouse III-Inserm, Toulouse, France
| | - D Tougeron
- University of Poitiers and Gastroenterology and Hepatology Department, Poitiers University Hospital, Poitiers
| | - J Taïeb
- Institut du Cancer Paris CARPEM, Université Paris Cité, Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris, Paris
| | - R Guimbaud
- Digestive Oncology Department, Rangueil Hospital, University Hospital of Toulouse, Toulouse
| |
Collapse
|
3
|
Tunbridge M, Perkins G, Lee M, Salehi T, Yuson C, Le A, Ryoo D, Kette F, Smith W, Gold M, Hissaria P. COVID vaccination can be completed in subjects with a history of allergic reactions to the vaccines or their components - experience from a specialist clinic in South Australia. Intern Med J 2022; 52:1884-1890. [PMID: 35848521 PMCID: PMC9350084 DOI: 10.1111/imj.15888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 07/10/2022] [Indexed: 11/28/2022]
Abstract
The development of vaccines against SARS-CoV2 has been a key public health response to the COVID-19 pandemic. However, since their introduction there have been reports of anaphylactic reactions in vaccinees with history of allergy. We developed an allergy testing protocol allowing vaccination with available COVID-19 vaccines in Australia. Patients referred to a state-wide COVID-19 vaccine allergy clinic between March and August 2021 with a history of allergy underwent skin prick testing and intradermal testing to both available vaccine formulations (BNT162b2, ChAdOx1-S), excipients (polyethylene glycol, polysorbate 80), excipient-containing medications, and controls. Where available, basophil activation testing was conducted. 53 patients underwent testing for possible excipient allergy (n = 19), previous non-COVID vaccine reaction (n = 13), or previous reaction to dose 1 of COVID-19 vaccine (n = 21). Patients were predominantly female (n = 43, 81%), aged 18-83 (median 54) years. 44 patients tested negative and 42 of these received at least their first dose of a COVID-19 vaccine. 9 patients tested positive to excipients or excipient-containing medication only (n = 3), or vaccines (n = 6). 5 patients were positive to just BNT162b2, 3/5 have been vaccinated with ChAdOx1-S. 1 who was skin test positive to both vaccines, but negative BAT to ChAdOx1-S was successfully vaccinated with ChAdOx1-S. Even in a high-risk population, most patients can be vaccinated with available COVID-19 vaccines. This paper reports local experiences using a combined allergy testing protocol with skin testing and BAT during the pandemic. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Matthew Tunbridge
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - Griffith Perkins
- University of Adelaide, Adelaide, Australia.,SA Pathology, Adelaide, Australia
| | - Maverick Lee
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia
| | - Tania Salehi
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia.,University of Adelaide, Adelaide, Australia
| | - Chino Yuson
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia
| | - Adriana Le
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia
| | - Dongjae Ryoo
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia
| | - Frank Kette
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia
| | - William Smith
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia
| | - Michael Gold
- Women's and Children's Hospital, Royal Adelaide Hospital, Adelaide, Australia
| | - Pravin Hissaria
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia.,SA Pathology, Adelaide, Australia
| |
Collapse
|
4
|
Ali SB, Perkins G, Ryoo D, Lee M, Tunbridge M, Yuson C, Smith W, Hissaria P, Le TT. AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy. Allergy Asthma Clin Immunol 2022; 18:22. [PMID: 35272714 PMCID: PMC8908291 DOI: 10.1186/s13223-022-00665-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/04/2022] [Indexed: 12/31/2022]
Abstract
BACKGROUND Immediate hypersensitivity reactions to COVID-19 vaccines have been postulated to be linked to their excipients, such as polyethylene glycol (PEG) in Pfizer Comirnaty, or polysorbate 80 and ethylenediaminetetracetic acid (EDTA) in AstraZeneca ChAdOx1-S [recombinant] (Vaxzevria). These excipients are found in a range of other products, including injectable and oral medications as well as intravenous radiocontrast media (RCM) and various cosmetic products. Patients with proven excipient allergy may be advised to avoid a COVID-19 vaccine containing that excipient and/or potentially cross-reactive excipients. This may result in individual patients not receiving vaccines, especially if an alternate option is not available, and on a broader level contribute to vaccine hesitancy. We present two cases of previously confirmed EDTA anaphylaxis with positive intradermal testing, who had negative Vaxzevria vaccine in-vivo testing and subsequently tolerated the vaccine. CASE 1: A patient with history of anaphylaxis to RCM and local anaesthetics (LA) had positive intradermal test (IDT) to EDTA nine years earlier. Skin testing to Vaxzeria vaccine (up to 1:10 IDT), Comirnaty vaccine (up to 1:10 IDT) and EDTA 0.3 mg/mL IDT were negative. However, following EDTA 3 mg/ml IDT, he developed immediate generalised urticaria without anaphylaxis. Basophil activation testing was negative to disodium EDTA, Vaxzevria and Cominarty vaccines. Given the negative in-vitro and in-vivo testing to Vaxzevria vaccine, he proceeded to Vaxzevria immunisation and tolerated both doses. CASE 2: A patient with history of anaphylaxis to RCM had positive skin testing to EDTA and RCM containing EDTA six years earlier. Following referral to COVID19 vaccine clinic, Vaxzevria vaccine (1:10 IDT) and Cominarty vaccine (1:10 IDT) were negative whilst EDTA was positive at 0.3 mg/mL IDT. He subsequently tolerated both Vaxzevria vaccinations. CONCLUSION Excipient allergy does not necessarily preclude a patient from receiving a vaccine containing that excipient. Allergy testing can help identify excipient-allergic patients who may still tolerate vaccination, which is important in situations where COVID-19 vaccination options are limited.
Collapse
Affiliation(s)
- Syed B Ali
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia.,Department of Immunopathology, SA Pathology, Adelaide, Australia
| | - Griffith Perkins
- Department of Immunopathology, SA Pathology, Adelaide, Australia.,School of Biological Sciences, University of Adelaide, Adelaide, Australia
| | - Dongjae Ryoo
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia
| | - Maverick Lee
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia
| | - Matthew Tunbridge
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia
| | - Chino Yuson
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia
| | - William Smith
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia
| | - Pravin Hissaria
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia.,Department of Immunopathology, SA Pathology, Adelaide, Australia
| | - Thanh-Thao Le
- Department of Clinical Immunology and Allergy, Le. Royal Adelaide Hospital, 1 Port Road, Adelaide, South Australia, 5000, Australia.
| |
Collapse
|
5
|
Troelnikov A, Perkins G, Yuson C, Ahamdie A, Balouch S, Hurtado PR, Hissaria P. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J Allergy Clin Immunol 2021; 148:91-95. [DOI: 10.1016/j.jaci.2021.04.032] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 04/22/2021] [Accepted: 04/28/2021] [Indexed: 12/31/2022]
|
6
|
Perkins G, Troelnikov A, Hissaria P. Reply. J Allergy Clin Immunol 2021; 148:902-903. [PMID: 34183167 DOI: 10.1016/j.jaci.2021.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 06/01/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Griffith Perkins
- SA Pathology, Adelaide, Australia; School of Biological Sciences, University of Adelaide, Adelaide, Australia
| | | | - Pravin Hissaria
- Immunology Department, Royal Adelaide Hospital, Adelaide, Australia.
| |
Collapse
|
7
|
Daïen C, Tan J, Audo R, Mielle J, Quek L, Krycer J, Angelatos A, Duraes M, Pinget G, Ni D, Robert R, Alam M, Amian M, Sierro F, Parmar A, Perkins G, Hoque S, Gosby A, Simpson S, Ribeiro R, Mackay C, Macia L. Gut-derived acetate promotes B10 cells with antiinflammatory effects. JCI Insight 2021; 6:144156. [PMID: 33729999 PMCID: PMC8119207 DOI: 10.1172/jci.insight.144156] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Accepted: 03/03/2021] [Indexed: 02/06/2023] Open
Abstract
Autoimmune diseases are characterized by a breakdown of immune tolerance partly due to environmental factors. The short-chain fatty acid acetate, derived mostly from gut microbial fermentation of dietary fiber, promotes antiinflammatory Tregs and protects mice from type 1 diabetes, colitis, and allergies. Here, we show that the effects of acetate extend to another important immune subset involved in tolerance, the IL-10-producing regulatory B cells (B10 cells). Acetate directly promoted B10 cell differentiation from mouse B1a cells both in vivo and in vitro. These effects were linked to metabolic changes through the increased production of acetyl-coenzyme A, which fueled the TCA cycle and promoted posttranslational lysine acetylation. Acetate also promoted B10 cells from human blood cells through similar mechanisms. Finally, we identified that dietary fiber supplementation in healthy individuals was associated with increased blood-derived B10 cells. Direct delivery of acetate or indirect delivery via diets or bacteria that produce acetate might be a promising approach to restore B10 cells in noncommunicable diseases.
Collapse
MESH Headings
- Acetates/blood
- Acetates/metabolism
- Acetates/pharmacology
- Acetyl Coenzyme A/metabolism
- Acetylation
- Animals
- Arthritis, Experimental/immunology
- Arthritis, Experimental/therapy
- B-Lymphocytes, Regulatory/drug effects
- B-Lymphocytes, Regulatory/physiology
- B-Lymphocytes, Regulatory/transplantation
- Cell Differentiation/drug effects
- Dietary Fiber/pharmacology
- Fatty Acids, Volatile/metabolism
- Fatty Acids, Volatile/pharmacology
- Female
- Humans
- Interleukin-10
- Male
- Mice, Inbred C57BL
- Mice, Mutant Strains
- Neutrophils/cytology
- Neutrophils/drug effects
- Receptors, G-Protein-Coupled/genetics
- Mice
Collapse
Affiliation(s)
- C.I. Daïen
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
- Department of Rheumatology, Montpellier Hospital, University of Montpellier, Montpellier, France
- Institute of Molecular Genetics of Montpellier, UMR5535, University of Montpellier, Montpellier, France
| | - J. Tan
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
- Human Health, Nuclear Science & Technology and Landmark Infrastructure (NSTLI) Australian Nuclear Science and Technology Organisation, New South Wales, Sydney, Australia
| | - R. Audo
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
- Department of Rheumatology, Montpellier Hospital, University of Montpellier, Montpellier, France
- Institute of Molecular Genetics of Montpellier, UMR5535, University of Montpellier, Montpellier, France
| | - J. Mielle
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
- Institute of Molecular Genetics of Montpellier, UMR5535, University of Montpellier, Montpellier, France
| | - L.E. Quek
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- School of Mathematics and Statistics and
| | - J.R. Krycer
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- School of Life and Environmental Sciences, The University of Sydney, New South Wales, Sydney, Australia
| | - A. Angelatos
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
| | - M. Duraes
- Department of Gynecology, Montpellier Hospital, University of Montpellier, Montpellier, France
| | - G. Pinget
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
| | - D. Ni
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
| | | | - M.J. Alam
- Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - M.C.B. Amian
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
- School of Life and Environmental Sciences, The University of Sydney, New South Wales, Sydney, Australia
| | - F. Sierro
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
- Human Health, Nuclear Science & Technology and Landmark Infrastructure (NSTLI) Australian Nuclear Science and Technology Organisation, New South Wales, Sydney, Australia
| | - A. Parmar
- Human Health, Nuclear Science & Technology and Landmark Infrastructure (NSTLI) Australian Nuclear Science and Technology Organisation, New South Wales, Sydney, Australia
- Brain and Mind Centre, The University of Sydney, New South Wales, Sydney, Australia
| | - G. Perkins
- Biosciences platform, NSTLI Australian Nuclear Science and Technology Organisation, New South Wales, Sydney, Australia
| | - S. Hoque
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- School of Mathematics and Statistics and
| | - A.K. Gosby
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- School of Life and Environmental Sciences, The University of Sydney, New South Wales, Sydney, Australia
| | - S.J. Simpson
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- School of Life and Environmental Sciences, The University of Sydney, New South Wales, Sydney, Australia
| | - R.V. Ribeiro
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- School of Life and Environmental Sciences, The University of Sydney, New South Wales, Sydney, Australia
| | | | - L. Macia
- Charles Perkins Centre, The University of Sydney, New South Wales, Sydney, Australia
- Faculty of Medicine and Health, The University of Sydney School of Medicine, New South Wales, Sydney, Australia
| |
Collapse
|
8
|
Wendeu-Foyet G, Fassier P, Perrod G, Perkins G, Coffin E, Deschasaux-Tanguy M, Julia C, Mamzer MF, Laurent-Puig P, Touvier M. CARPEM-LYNCH : un programme de recherche qui lie des données hospitalières aux données de la cohorte NutriNet-Santé pour tester le consentement dynamique. NUTR CLIN METAB 2021. [DOI: 10.1016/j.nupar.2021.01.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Wendeu-Foyet G, Fassier P, Perrod G, Perkins G, Coffin E, Deschasaux M, Julia C, Mamzer MF, Laurent-Puig P, Touvier M. CARPEM-LYNCH: a program linking hospital and NutriNet-Santé e-cohort data to test dynamic consent. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Technological innovations have contributed to rapid changes in translational research, allowing greater amounts of shared data on an unprecedented scale. However, methods for involving patients in research have not kept pace with changes in research capacity. Modern tools offering more flexibility in the management of patient consent are needed. The CARPEM-LYNCH program aims to explore the acceptance and feasibility of the concept of dynamic informed consent. It is a pilot program to test a research platform at the interface between hospital follow-up clinical data and data provided by patients through the NutriNet-Santé e-cohort platform.
Methods
Patients diagnosed with Lynch Syndrome followed at the European hospital Georges Pompidou (HEGP) are recruited and followed-up within the NutriNet-Santé online platform. In addition to generic NutriNet questionnaires (very detailed data on diet, physical activity, lifestyle, etc.), participants receive specific questionnaires related to their syndrome, perception of nutritional risk factors, and quality of life. Clinical data collected during standard hospital care will be linked to NutriNet data for participants who provide a dynamic consent. This dispositive will allow to investigate multiple dimensions of dietary behaviors and their health impact in these at-risk patients.
Results
The pilot phase has started. The first 20 patients have been included, showing good acceptance of the dynamic consent. Qualitative analysis of their responses is ongoing to optimize tools before large-scale deployment and extension to other hospital centers.
Conclusions
This experience of merging hospital and e-cohort data through dynamic consent to advance knowledge on health impact of diet and lifestyle in Lynch patients opens up a multitude of perspectives.
Key messages
Dynamic informed consent offers opportunities for data sharing between clinicians, researchers and patients with a promising impact on translational research. Dynamic informed consent can provide practical and sustainable solutions to the challenges of recruiting and retaining participants, managing consent and it can also be a source of economic efficiency.
Collapse
Affiliation(s)
- G Wendeu-Foyet
- Nutritional Epidemiology Research Team, Sorbonne Paris Nord (Paris 13) University, Inserm U1153, Inrae U1125, Cnam, Bobigny, France
| | - P Fassier
- Nutritional Epidemiology Research Team, Sorbonne Paris Nord (Paris 13) University, Inserm U1153, Inrae U1125, Cnam, Bobigny, France
| | - G Perrod
- Gastroenterology and Endoscopy division, European hospital Georges Pompidou, Assistance Publique-Hôpitaux de Paris, University Paris-Descartes Sorbonne-Paris Cité, Paris, France
| | - G Perkins
- Oncogenetic division, AP-HP, European hospital Georges Pompidou, Paris, France
| | - E Coffin
- Gastro-entérology division, AP-HP, Cochin hospital, University of Paris, Paris, France
| | - M Deschasaux
- Nutritional Epidemiology Research Team, Sorbonne Paris Nord (Paris 13) University, Inserm U1153, Inrae U1125, Cnam, Bobigny, France
| | - C Julia
- Nutritional Epidemiology Research Team, Sorbonne Paris Nord (Paris 13) University, Inserm U1153, Inrae U1125, Cnam, Bobigny, France
- Public Health Department, Avicenne Hospital, AP-HP, Bobigny, France
| | - M-F Mamzer
- Laboratory of medical ethics, University of Paris-Descartes EA 4569, Neckers children's hospital, AP-HP, Paris, France
| | - P Laurent-Puig
- Research center of Cordeliers, INSERM, Sorbonne University, USPC, Paris-Descartes, Paris-Diderot University, EPIGENETEC, Paris, France
| | - M Touvier
- Nutritional Epidemiology Research Team, Sorbonne Paris Nord (Paris 13) University, Inserm U1153, Inrae U1125, Cnam, Bobigny, France
| |
Collapse
|
10
|
Olasveengen T, Castrén M, Handley A, Kuzovlev A, Monsieurs KG, Perkins G, Raffay V, Ristagno G, Semeraro F, Smyth M, Soar J, Svavarsdóttir H. Basismaßnahmen zur Wiederbelebung Erwachsener. Notf Rett Med 2020; 23:246-247. [PMID: 32536799 PMCID: PMC7284673 DOI: 10.1007/s10049-020-00719-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- T. Olasveengen
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - M. Castrén
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - A. Handley
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - A. Kuzovlev
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - K. G. Monsieurs
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - G. Perkins
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - V. Raffay
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - G. Ristagno
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - F. Semeraro
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - M. Smyth
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - J. Soar
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| | - H. Svavarsdóttir
- European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel, Belgien
| |
Collapse
|
11
|
Böttiger BW, Lockey A, Georgiou M, Greif R, Monsieurs KG, Mpotos N, Nikolaou N, Nolan J, Perkins G, Semeraro F, Wingen S. KIDS SAVE LIVES: ERC Position statement on schoolteachers' education and qualification in resuscitation. Resuscitation 2020; 151:87-90. [PMID: 32339597 PMCID: PMC7194866 DOI: 10.1016/j.resuscitation.2020.04.021] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 04/14/2020] [Accepted: 04/16/2020] [Indexed: 12/11/2022]
Affiliation(s)
- B W Böttiger
- Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany.
| | - A Lockey
- Emergency Department, Calderdale Royal Hospital, Halifax, United Kingdom
| | - M Georgiou
- American Medical Center, Nicosia, Cyprus
| | - R Greif
- Department of Anesthesiology and Pain Therapy, Bern University Hospital, University of Bern, Bern, Switzerland; School of Medicine, Sigmund Freud University Vienna, Vienna, Austria
| | - K G Monsieurs
- Emergency Department, Antwerp University Hospital, Edegem, Belgium
| | - N Mpotos
- Faculty of Medicine and Health Sciences, Ghent University and Department of Emergency Medicine, St. Lucas General Hospital, Ghent, Belgium
| | - N Nikolaou
- Department of Cardiology and Cardiac Intensive Care, Konstantopouleio General Hospital, Athens, Greece
| | - J Nolan
- Warwick Clinical Trials Unit, University of Warwick and Department of Anaesthesia and Intensive Care Medicine, Royal United Hospital, Bath, United Kingdom
| | - G Perkins
- Warwick Clinical Trials Unit and University Hospitals Birmingham NHS Foundation Trust, University of Warwick, Coventry, United Kingdom
| | - F Semeraro
- Department of Anaesthesia, Intensive Care and EMS, Maggiore Hospital, Bologna, Italy
| | - S Wingen
- Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
12
|
Temple M, Tarek A, Baharani J, Perkins G, Sitch A, THOMAS M. SUN-179 The AKORDD study of AKI Outreach – experience from the UK’s first controlled trial in unselected acute kidney injury. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Palmieri L, Dubreuil O, Hautefeuille V, Bachet J, Trouilloud I, Locher C, Coriat R, Moryoussef F, Landi B, Perkins G, Doat S. Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Lesus J, Arias K, Kulaga J, Sobkiv S, Patel A, Babu V, Kambalyal A, Patel M, Padron F, Mozaffari P, Jayakumar A, Ghatalah L, Laban N, Bahari R, Perkins G, Lysakowski A. Why study inner ear hair cell mitochondria? HNO 2019; 67:429-433. [PMID: 30969353 DOI: 10.1007/s00106-019-0662-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
In several systems of the body (muscle, liver, nerves), new studies have examined the internal structure of mitochondria and brought to light striking new findings about how mitochondria are constructed and how their structure affects cell function. In the inner ear field, however, we have little structural knowledge about hair cell and supporting cell mitochondria, and virtually none about mitochondrial subtypes or how they function in health and disease. The need for such knowledge is discussed in this short review.
Collapse
Affiliation(s)
- J Lesus
- Dept. of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St., M/C 512, 60612, Chicago, IL, USA
| | - K Arias
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - J Kulaga
- Dept. of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St., M/C 512, 60612, Chicago, IL, USA
| | - S Sobkiv
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - A Patel
- Dept. of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St., M/C 512, 60612, Chicago, IL, USA
| | - V Babu
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - A Kambalyal
- Dept. of Economics, University of Illinois at Chicago, Chicago, IL, USA
| | - M Patel
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - F Padron
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - P Mozaffari
- Dept. of Economics, University of Illinois at Chicago, Chicago, IL, USA
| | - A Jayakumar
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - L Ghatalah
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - N Laban
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - R Bahari
- Dept. of Biological Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - G Perkins
- National Center for Microscopy and Imaging Research (NCMIR), University of California, San Diego, La Jolla, CA, USA
| | - A Lysakowski
- Dept. of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St., M/C 512, 60612, Chicago, IL, USA. .,Dept. of Otolaryngology, University of Illinois at Chicago, Chicago, IL, USA.
| |
Collapse
|
15
|
Poole J, McDowell C, Lall R, Perkins G, McAuley D, Gao F, Young D. Individual patient data analysis of tidal volumes used in three large randomized control trials involving patients with acute respiratory distress syndrome. Br J Anaesth 2018; 118:570-575. [PMID: 28403395 PMCID: PMC8542892 DOI: 10.1093/bja/aew465] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/19/2016] [Indexed: 01/20/2023] Open
Abstract
Background. The acute respiratory distress syndrome (ARDS) is a condition with a high mortality and morbidity. Mechanical ventilation prevents immediate mortality but may further damage patients' lungs. Low tidal volume lung-protective strategies have been shown to increase survival by reducing this iatrogenic damage. Current guidelines recommend tidal volumes of 6-8 ml kg -1 of predicted body weight. We used data from three large randomized controlled trials of treatments for ARDS to determine compliance with these recommendations. Methods. We used the tidal volume recorded at randomization for all patients in the OSCAR, HARP-2, and BALTI-2 studies. In addition, we used the ventilation data for control arm patients in OSCAR and all patients in HARP-2 at days 1 and 7 after randomization. Results. The three trials enrolled 1660 patients, with tidal volume data available at least at one time point in 1412 patients. Compliance with the 6-8 ml kg -1 recommendation for tidal volume ranged from 20 to 39% of patients across all time points in all three trials. Conclusion. Poor compliance with the guidelines for tidal volume in patients with ARDS has been demonstrated before in case series, but not in clinical trials where the patient population is specifically selected against standard ARDS diagnostic criteria and the investigators were encouraged to use low tidal volumes. This study may indicate a need to improve implementation and compliance with protective lung ventilation.
Collapse
Affiliation(s)
- J Poole
- Department of Anaesthesia and Critical Care, John Radcliffe Hospital, Oxford, UK
| | - C McDowell
- Northern Ireland Clinical Trials Unit, Queen's University of Belfast, UK
| | - R Lall
- Clinical Trials Unit, University of Warwick, UK
| | - G Perkins
- Clinical Trials Unit, University of Warwick, UK.,Warwick Medical School, University of Warwick, UK.,Directorate of Anaesthetics, Heart of England NHS Foundation Trust, Birmingham, UK
| | - D McAuley
- Centre for Experimental Medicine, Queen's University of Belfast, UK.,Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
| | - F Gao
- Directorate of Anaesthetics, Heart of England NHS Foundation Trust, Birmingham, UK.,Institute of Inflammation and Ageing, University of Birmingham, UK
| | - D Young
- Nuffield Department of Clinical Neurosciences, University of Oxford, UK
| |
Collapse
|
16
|
Ryan CW, Bishop K, Blaney DD, Britton SJ, Cantone F, Egan C, Elrod MG, Frye CW, Maxted AM, Perkins G. Public health response to an imported case of canine melioidosis. Zoonoses Public Health 2018; 65:420-424. [PMID: 29451368 DOI: 10.1111/zph.12450] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Indexed: 12/01/2022]
Abstract
Melioidosis in humans presents variably as fulminant sepsis, pneumonia, skin infection and solid organ abscesses. It is caused by Burkholderia pseudomallei, which in the United States is classified as a select agent, with "potential to pose a severe threat to both human and animal health, to plant health or to animal and plant products" (Federal Select Agent Program, http://www.selectagents.gov/, accessed 22 September 2016). Burkholderia pseudomallei is found in soil and surface water in the tropics, especially South-East Asia and northern Australia, where melioidosis is endemic. Human cases are rare in the United States and are usually associated with travel to endemic areas. Burkholderia pseudomallei can also infect animals. We describe a multijurisdictional public health response to a case of subclinical urinary B. pseudomallei infection in a dog that had been adopted into upstate New York from a shelter in Thailand. Investigation disclosed three human contacts with single, low-risk exposures to the dog's urine at his residence, and 16 human contacts with possible exposure to his urine or culture isolates at a veterinary hospital. Contacts were offered various combinations of symptom/fever monitoring, baseline and repeat B. pseudomallei serologic testing, and antibiotic post-exposure prophylaxis, depending on the nature of their exposure and their personal medical histories. The dog's owner accepted recommendations from public health authorities and veterinary clinicians for humane euthanasia. A number of animal rescue organizations actively facilitate adoptions into the United States of shelter dogs from South-East Asia. This may result in importation of B. pseudomallei into almost any community, with implications for human and animal health.
Collapse
Affiliation(s)
- C W Ryan
- Broome County Health Department, Binghamton, NY, USA
| | - K Bishop
- Tompkins County Health Department, Ithaca, NY, USA
| | - D D Blaney
- Bacterial Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - S J Britton
- Broome County Health Department, Binghamton, NY, USA.,New York Medical College, Valhalla, NY, USA
| | - F Cantone
- Office of Emergency Management, Environmental Health and Safety, Cornell University, Ithaca, NY, USA
| | - C Egan
- New York State Department of Health, Biodefense Laboratory, Wadsworth Center, New York, NY, USA
| | - M G Elrod
- Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - C W Frye
- Sports Medicine and Rehabilitation and Resident in Clinical Nutrition, Cornell University Hospital for Animals, Ithaca, NY, USA
| | - A M Maxted
- New York State Department of Health, Bureau of Communicable Disease Control, New York, NY, USA
| | - G Perkins
- College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| |
Collapse
|
17
|
Wagener J, Smith SV, Soni N, Marjanovic-Painter B, Zinn C, Van de Wiele C, D’Asseler Y, Perkins G, Zeevaart JR, Sathekge M. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Nuklearmedizin 2018; 52:222-7. [DOI: 10.3413/nukmed-0599-13-06] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Accepted: 09/23/2013] [Indexed: 11/20/2022]
Abstract
Summary
195mPt-cisplatin is regarded as a promising imaging agent for optimizing dosage in patients receiving cisplatin chemotherapy. Methods: We investigated the whole-body distribution and radiation dosimetry of 195mPt-cisplatin in humans. Whole-body scans were obtained up to 144 h after intravenous injection of 112.4 MBq 195mPt-cisplatin in each of five subjects. Blood samples were taken at various times up to 144 h after injection. Urine was collected up to 114 h after injection for calculation of renal clearance and whole-body clearance. Time/activity curves were generated by fitting the organ-specific geometric mean counts, obtained from regions of interest, on the respective images as a function of the time after injection. OLINDA software package was applied to calculate the absorbed radiation dose for various organs. Results: Most of the activity (32 ± 4%) was excreted in the urine during the first 5 h. The effective clearance half-life derived from extrapolation of the whole-body curve was 40 hours (1.7 days). On average, the highest dose was received by the kidneys (mean dose received 2.68 ± 1.5 mGy/MBq), followed by the spleen (mean dose received 1.6 ± 0.8 mGy/MBq) followed by the liver (mean dose received 1.45 ± 0.38 mGy/MBq). The estimated mean effective dose for the adult subject was 0.185 ± 0.034 mSv/MBq. Conclusion: 195mPt-cisplatin proved a safe radiopharmaceutical with a favourable bio distribution for early and delayed imaging of pathology above the diaphragm. The ED obtained was 0.185 ± 0.034 mSv/MBq. The highest organ dose was received by the kidneys (2.68 ± 1.5 mGy/ MBq).
Collapse
|
18
|
Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Ann Oncol 2017; 28:824-830. [PMID: 28031175 DOI: 10.1093/annonc/mdw687] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Indexed: 12/14/2022] Open
Abstract
Background RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial (cetuximab + FOLFOX vs FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III colon cancer. Patients and methods Exons 2, 3 and 4 of KRAS and NRAS, and BRAF exons 11 and 15, were sequenced using the Ampliseq colon-lung cancer panel version 2, in PETACC8 trial pts who consented to translational research. The impact of cetuximab on time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS) was investigated in pts with tumours harbouring RAS and BRAF WT, and RAS mutations. The prognostic value of each individual mutation was also tested. Results Among the 2559 pts analysed, 745 pts (29%) were known to have KRAS exon 2 mutations and 163 pts (6.4%) the BRAF V600E mutation. Of the remaining 1651 pts, 1054 were assessed by NGS, showing that a further 227 pts (21%) had KRAS exon 2, 3, 4 or NRAS exon 2, 3, 4 mutations, and that 46 pts (4.4%) had a newly diagnosed BRAF mutation. Cetuximab added to FOLFOX did not significantly improve TTR, DFS or OS in pts with RAS WT or RAS and BRAF WT tumours (HR 0.77-1.03, all P > 0.05). Cetuximab addition was not either significantly deleterious in RAS mutant pts or in pts with rare RAS or BRAF mutations. In the overall trial population, NRAS and KRAS codon 61 mutations were the only rare mutations with the same pejorative prognostic value as KRAS exon 2 or BRAF V600E mutations. Conclusion Though not significant, the clinically relevant 0.76 adjusted HR observed for DFS in favour of adding cetuximab to FOLFOX, in full RAS and BRAF WT stage III colon cancer pts, may justify a new randomized controlled trial testing EGFR inhibitors in this setting. Clinical trial number This is an ancillary study of the PETACC8 trial: EUDRACT 2005-003463-23.
Collapse
Affiliation(s)
- J Taieb
- Paris Descartes University, Paris Sorbonne cité, Department of Digestive Oncology, HEGP, Paris, France
| | - R Balogoun
- Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France
| | - K Le Malicot
- Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France
| | - J Tabernero
- Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Universitat Autònoma de Barcelona, Spanish Gastrointestinal Tumours TTD Group, Barcelona, Spain
| | - E Mini
- Department of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy
| | - G Folprecht
- Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
| | - J-L Van Laethem
- Department of Gastroenterology, Hôpital Universitaire Erasme, Brussels, Belgium
| | - J-F Emile
- Pathology Department, Ambroise Paré Hospital, Boulogne, France
| | - C Mulot
- Université Paris Descartes, Sorbonne Paris Cité, CRB EPIGENETEC, INSERM UMR-S1147, Paris, France
| | - S Fratté
- Department of Gastroenterology, Centre Hospitalier de Belfort-Montbeliard, Belfort, France
| | - C-B Levaché
- Department of Radiotherapy and Medical Oncology, Polyclinique Francheville, Périgueux, France
| | - L Saban-Roche
- Department of medical Oncology, Institut de Cancerologie de la Loire, Saint-Priest-En-Jarez, France
| | - J Thaler
- Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria
| | - L N Petersen
- Department of Oncology, Rigshospitalet, København, Denmark
| | - J Bridgewater
- UCL Cancer Institute, University College London, London, UK
| | - G Perkins
- Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France.,Université Sorbonne Paris Cité, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pères, Equipe labélisée LIGUE Contre le Cancer, Paris, France
| | - C Lepage
- Hepato-Gastroenterology Department, Dijon University Hospital and INSERM U 866, Dijon, France
| | - E Van Cutsem
- Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium
| | - A Zaanan
- Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France.,Department of Digestive Oncology, European Georges Pompidou Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - P Laurent-Puig
- Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France
| | | |
Collapse
|
19
|
Abstract
The efficient characterization of genetic and epigenetic alterations in oncology, virology, or prenatal diagnostics requires highly sensitive and specific high-throughput approaches. Nevertheless, with the use of conventional methods, sensitivity and specificity were largely limited. By partitioning individual target molecules within distinct compartments, digital PCR (dPCR) could overcome these limitations and detect very rare sequences with unprecedented precision and sensitivity. In dPCR, the sample is diluted such that each individual partition will contain no more than one target sequence. Following the assay reaction, the dPCR process provides an absolute value and analyzable quantitative data. The recent coupling of dPCR with microfluidic systems in commercial platforms should lead to an essential tool for the management of patients with cancer, especially adapted to the analysis of precious samples. Applications in cancer research range from the analysis of tumor heterogeneity to that of a range of body fluids. Droplet-based dPCR is indeed particularly appropriate for the emerging field of liquid biopsy analysis. In this review, following an overview of the development in dPCR technology and different strategies based on the use of microcompartments, we will focus particularly on the applications and latest development of microfluidic droplet-based dPCR in oncology.
Collapse
Affiliation(s)
- G Perkins
- Université Sorbonne Paris Cité, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pères, Equipe labélisée LIGUE Contre le Cancer, Paris, France; European Georges Pompidou Hospital, AP-HP - Paris Descartes University, Paris, France
| | - H Lu
- Université Sorbonne Paris Cité, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pères, Equipe labélisée LIGUE Contre le Cancer, Paris, France
| | - F Garlan
- Université Sorbonne Paris Cité, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pères, Equipe labélisée LIGUE Contre le Cancer, Paris, France
| | - V Taly
- Université Sorbonne Paris Cité, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pères, Equipe labélisée LIGUE Contre le Cancer, Paris, France.
| |
Collapse
|
20
|
Lapeyre-Prost A, Perkins G, Vallee M, Pozet A, Tougeron D, Maillet M, Locher C, Dreanic J, Legoux J, Lievre A, Lecaille C, Sabate JM, Mary F, Bonnetain F, Jaulmes-Bouillot H, Landi B, Taieb J. End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEO study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw384.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Zaanan A, Garlan F, Didelot A, Perkins G, Siauve N, Blons H, Taieb J, Taly V, Laurent-Puig P. Prognostic value of circulating tumor DNA in advanced colorectal cancer patients: Quantification of hypermethylated or mutant sequences using picoliter droplet digital PC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.78] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Taieb J, Le Malicot K, Balogoum R, Tabernero J, Mini E, Folprecht G, van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Sanchez E, Bridgewater J, Perkins G, Lepage C, Zaanan A, Laurent-Puig P. Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Perkins G, Fabre E, Fallet V, Blons H, Pecuchet N, Gounant V, Gibault L, Michel-Jeljeli E, Antoine M, Roux E, Wislez M, Le Corre D, Leroy K, Lacave R, Taieb J, Cadranel J, Laurent-Puig P. Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Cummings MC, Greaves J, Shukor RA, Perkins G, Ross J. Technical proficiency in cytopathology: assessment through external quality assurance. Cytopathology 2016; 28:149-156. [DOI: 10.1111/cyt.12373] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/28/2016] [Indexed: 11/28/2022]
Affiliation(s)
- M. C. Cummings
- Cytopathology; RCPAQAP; St Leonards Sydney NSW Australia
- UQ Centre for Clinical Research; The University of Queensland; Herston Brisbane Qld Australia
- Pathology Queensland: The Royal Brisbane & Women's Hospital; Brisbane Qld Australia
| | - J. Greaves
- Cytopathology; RCPAQAP; St Leonards Sydney NSW Australia
| | - R. A. Shukor
- Sullivan Nicolaides Pathology; Indooroopilly Brisbane Qld Australia
| | | | - J. Ross
- Cytopathology; RCPAQAP; St Leonards Sydney NSW Australia
| |
Collapse
|
25
|
Howells P, Thickett D, Knox C, Park D, Gao F, Tucker O, Whitehouse T, McAuley D, Perkins G. The impact of the acute respiratory distress syndrome on outcome after oesophagectomy. Br J Anaesth 2016; 117:375-81. [PMID: 27440674 DOI: 10.1093/bja/aew178] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/16/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The Acute Respiratory Distress Syndrome (ARDS) is a serious complication of major surgery and consumes substantial healthcare resources. Oesophagectomy is associated with high rates of ARDS. The aim of this study was to characterize patients and identify risk factors for developing ARDS after oesophagectomy. METHODS A secondary analysis of data from 331 patients gathered during the Beta Agonists Lung Injury Prevention Trial was undertaken. Characteristics and outcomes of patients with early (first 72 h postoperatively) and late (after 72 h) ARDS were determined. Linear and multivariate regression analysis was used to study the differences between early and late ARDS and identify risk factors. RESULTS ARDS was associated with more non-respiratory organ failure (early 44.1%, late 75.0%, no ARDS 27.6% P<0.001), longer ICU stay (mean early 12.1, late 20.2, no ARDS 7.3 days P<0.001) and longer hospital stay (mean early 18.1, late 24.5, no ARDS 14.2 days P<0.001) but no difference in mortality or quality of life. Older patients (OR 1.06 (1.00 to 1.13), P=0.045) and those with mid-oesophageal tumours (OR 7.48 (1.62-34.5), P=0.010) had a higher risk for ARDS. CONCLUSIONS Early and late ARDS after oesophagectomy increases intensive care and hospital length of stay. Given the high incidence of ARDS, cohorts of patients undergoing oesophagectomy may be useful as models for studies investigating ARDS prevention and treatment. Further investigations aimed at reducing perioperative ARDS are warranted.
Collapse
Affiliation(s)
- P Howells
- Institute for Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital Birmingham, B15 2TT, UK
| | - D Thickett
- Institute for Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital Birmingham, B15 2TT, UK
| | - C Knox
- Mathematics and Statistics Help Centre, University of Sheffield, Sheffield S10 2HL, UK
| | - D Park
- Department of Intensive Care Medicine, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK
| | - F Gao
- Institute for Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital Birmingham, B15 2TT, UK Department of Intensive Care Medicine, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK
| | - O Tucker
- Department of Upper Gastrointestinal Surgery, University Hospitals Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TT, UK
| | - T Whitehouse
- Department of Anaesthesia and Critical Care Medicine, University Hospitals Birmingham, Queen Elizabeth Hospital, B15 2TT UK
| | - D McAuley
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK Department of Intensive Care Medicine, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK
| | - G Perkins
- Department of Intensive Care Medicine, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
| |
Collapse
|
26
|
McDonald C, Henricson E, Oskarsson B, Aguilar C, Nicorici A, Joyce N, Reddy D, Wagner A, deBie E, Goude E, Abresch R, Villareal F, Perkins G, Hathout Y, Dugar S, Schreiner G. Epicatechin enhances mitochondrial biogenesis, increases dystrophin and utrophin, increases follistatin while decreasing myostatin, and improves skeletal muscle exercise response in adults with Becker muscular dystrophy (BMD). Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.456] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Aouadi S, McGarry M, Hammoud R, Torfeh T, Perkins G, Al-Hammadi N. MO-F-CAMPUS-J-05: Toward MRI-Only Radiotherapy: Novel Tissue Segmentation and Pseudo-CT Generation Techniques Based On T1 MRI Sequences. Med Phys 2015. [DOI: 10.1118/1.4925451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Torfeh T, Hammoud R, Perkins G, McGarry M, Al-Hammadi N. SU-E-I-59: Virtual Phantom: A First Step to a Comprehensive Automated Quality Control Program for Magnetic Resonance Image Guided Applications. Med Phys 2015. [DOI: 10.1118/1.4924056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
Perkins G. SP-0509: MR Imaging in Radiotherapy: The evolving role of the RTT. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40505-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Zhao HW, Gu XQ, Chailangkarn T, Perkins G, Callacondo D, Appenzeller O, Poulsen O, Zhou D, Muotri AR, Haddad GG. Altered iPSC-derived neurons' sodium channel properties in subjects with Monge's disease. Neuroscience 2015; 288:187-99. [PMID: 25559931 DOI: 10.1016/j.neuroscience.2014.12.039] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Revised: 12/22/2014] [Accepted: 12/23/2014] [Indexed: 12/17/2022]
Abstract
Monge's disease, also known as chronic mountain sickness (CMS), is a disease that potentially threatens more than 140 million highlanders during extended time living at high altitudes (over 2500m). The prevalence of CMS in Andeans is about 15-20%, suggesting that the majority of highlanders (non-CMS) are rather healthy at high altitudes; however, CMS subjects experience severe hypoxemia, erythrocytosis and many neurologic manifestations including migraine, headache, mental fatigue, confusion, and memory loss. The underlying mechanisms of CMS neuropathology are not well understood and no ideal treatment is available to prevent or cure CMS, except for phlebotomy. In the current study, we reprogrammed fibroblast cells from both CMS and non-CMS subjects' skin biopsies into the induced pluripotent stem cells (iPSCs), then differentiated into neurons and compared their neuronal properties. We discovered that CMS neurons were much less excitable (higher rheobase) than non-CMS neurons. This decreased excitability was not caused by differences in passive neuronal properties, but instead by a significantly lowered Na(+) channel current density and by a shift of the voltage-conductance curve in the depolarization direction. Our findings provide, for the first time, evidence of a neuronal abnormality in CMS subjects as compared to non-CMS subjects, hoping that such studies can pave the way to a better understanding of the neuropathology in CMS.
Collapse
Affiliation(s)
- H W Zhao
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
| | - X Q Gu
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
| | - T Chailangkarn
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA
| | - G Perkins
- National Center for Microscopy and Imaging Research, University of California San Diego, La Jolla, CA, USA
| | - D Callacondo
- Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima 36, Peru
| | - O Appenzeller
- New Mexico Health Enhancement and Marathon Clinics Research Foundation, Albuquerque, NM 87122, USA
| | - O Poulsen
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
| | - D Zhou
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
| | - A R Muotri
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA; The Rady Children's Hospital, San Diego, CA 92123, USA
| | - G G Haddad
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA; The Rady Children's Hospital, San Diego, CA 92123, USA.
| |
Collapse
|
31
|
Dancer R, Parekh D, Perkins G, Thickett D. S97 Long Term Survival In Patients Who Undergo Oesophagectomy Is Lower In Patients Who Develop Post-operative Acute Respiratory Distress Syndrome. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Lad S, Seely J, Elmaadawi M, Peddle S, Perkins G, Robertson S, Ibach K, Haggar F, Arnaout A. Juvenile Papillomatosis: A Case Report and Literature Review. Clin Breast Cancer 2014; 14:e103-5. [DOI: 10.1016/j.clbc.2014.03.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 06/20/2013] [Accepted: 03/24/2014] [Indexed: 11/28/2022]
|
33
|
Petric P, Berger D, Hammoud R, Divakar S, Riyas M, Perkins G, Sheim S, El Kaissi T, Paloor S, Hayes J, Azar K, Al-Hammadi N. A Tool for Pretreatment Estimation of Brachytherapy Dose Contribution to Pelvic Lymph Nodes in Cervix Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, de Bono JS. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 2014; 111:828-36. [PMID: 24983367 PMCID: PMC4150267 DOI: 10.1038/bjc.2014.350] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Revised: 05/14/2014] [Accepted: 06/02/2014] [Indexed: 12/22/2022] Open
Abstract
Background: Predictive biomarker development is a key challenge for novel cancer therapeutics. We explored the feasibility of next-generation sequencing (NGS) to validate exploratory genomic biomarkers that impact phase I trial selection. Methods: We prospectively enrolled 158 patients with advanced solid tumours referred for phase I clinical trials at the Royal Marsden Hospital (October 2012 to March 2013). After fresh and/or archived tumour tissue were obtained, 93 patients remained candidates for phase I trials. Results from tumour sequencing on the Illumina MiSeq were cross-validated in 27 out of 93 patients on the Ion Torrent Personal Genome Machine (IT-PGM) blinded to results. MiSeq validation with Sequenom MassARRAY OncoCarta 1.0 (Sequenom Inc., San Diego, CA, USA) was performed in a separate cohort. Results: We found 97% concordance of mutation calls by MiSeq and IT-PGM at a variant allele frequency ⩾13% and ⩾500 × depth coverage, and 91% concordance between MiSeq and Sequenom. Common ‘actionable' mutations involved deoxyribonucleic acid (DNA) repair (51%), RAS-RAF-MEK (35%), Wnt (26%), and PI3K-AKT-mTOR (24%) signalling. Out of 53, 29 (55%) patients participating in phase I trials were recommended based on identified actionable mutations. Conclusions: Targeted high-coverage NGS panels are a highly feasible single-centre technology well-suited to cross-platform validation, enrichment of trials with molecularly defined populations and hypothesis testing early in drug development.
Collapse
Affiliation(s)
- M Ong
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| | - S Carreira
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| | - J Goodall
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| | - J Mateo
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| | - I Figueiredo
- Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - D N Rodrigues
- Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - G Perkins
- Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - G Seed
- Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - T A Yap
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| | - G Attard
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| | - J S de Bono
- 1] Cancer Biomarkers Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK [2] Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
| |
Collapse
|
35
|
Perkins G, McGarry M, Torfeh T, Hammoud R, Fierro D, Al Hammadi N. OC-0181: Optimization of a novel multi-echo 3D UTE volumetric sequence for tissue segmentation in MRI-only RT planning. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30286-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Perkins G, McGarry M, Hammoud R, Divakar S, Riyas M, Torfeh T, Al Hammadi N. MRI-Based Radiation Therapy Planning of Prostate Cancer: Clinical Feasibility and Assessment of Dosimetric Accuracy for Different Treatment Techniques. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Pappas E, Maris T, Hammoud R, Perkins G, Al Hammadi N. An Innovative Method for Patient-Specific Pretreatment Plan Verification (PTPV) in Head and Neck Radiation Therapy Treatments: Preliminary Results. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.2004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
38
|
Boisson F, Wimberley CJ, Lehnert W, Zahra D, Pham T, Perkins G, Hamze H, Gregoire MC, Reilhac A. NEMA NU 4-2008 validation and applications of the PET-SORTEO Monte Carlo simulations platform for the geometry of the Inveon PET preclinical scanner. Phys Med Biol 2013; 58:6749-63. [DOI: 10.1088/0031-9155/58/19/6749] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
39
|
Sharif A, Paloor S, Sheim S, McGarry M, Pienaar S, Perkins G, Hammoud R, Al Hammadi N. SU-E-J-177: Comparison Between VMAT CT Planning and Segmented MRI Images with Assigned Bulk Density: A Dosimetric Study for Intact Prostate Patients. Med Phys 2013. [DOI: 10.1118/1.4814389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
McLellan J, McGarry M, Hammoud R, Riyas M, Divakar S, Al-Hammadi N, Perkins G. OC-0347: Adjuvant RT for Gastric Cancer: A dosimetric comparison of 3DCRT, RapidArcÆ and conventional IMRT techniques. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32653-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
McGarry M, Perkins G, Hammoud R, Torfeh T, Divakar S, Riyas M, Al-Hammadi N. OC-0074: Radiation therapist led quality assurance of a CT-MRI SIM localisation protocol for patients undergoing H&N RT. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32380-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Torfeh T, Perkins G, McGarry M, Al-Hammadi N, Hammoud R. EP-1287: Software module for the characterization of geometric distortion in MRI-SIM using a large field of view phantom. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33593-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Sathyamurthy R, Manney S, Webster C, Krishna T, Perkins G, Mansur AH. P3 Oxidative Distress and Antioxidants in Severe Asthma: Abstract P3 Table 1. Thorax 2012. [DOI: 10.1136/thoraxjnl-2012-202678.144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Perkins G, Hammoud R, Pienaar S, Paloor S, Al Hammadi N. A Novel Open Architecture Purpose Built Phased Coil Array for Head and Neck MR-SIM: Characterization, Protocol Optimization, and Imaging Performance Using Subjects Immobilized in the Treatment Position. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Hammoud R, Perkins G, Paloor S, Al Hammadi N. QA Procedures for the Assessment of Geometric Accuracy for MRI-SIM Using a Novel Large Field of View Phantom: System Performance Tests and Validation of Clinical Protocols. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Kydd JH, Slater J, Osterrieder N, Lunn DP, Antczak DF, Azab W, Balasuriya U, Barnett C, Brosnahan M, Cook C, Damiani A, Elton D, Frampton A, Gilkerson J, Goehring L, Horohov D, Maxwell L, Minke J, Morley P, Nauwynck H, Newton R, Perkins G, Pusterla N, Soboll-Hussey G, Traub-Dargatz J, Townsend H, Van de walle GR, Wagner B. Third International Havemeyer Workshop on Equine Herpesvirus type 1. Equine Vet J 2012; 44:513-7. [DOI: 10.1111/j.2042-3306.2012.00604.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Mathew J, Paloor S, Riyas M, Divakar S, Perkins G, Hammoud R, Al-Hammadi N. SU-E-T-649: Evaluation of RapidArc- Based Stereotactic Cranial Radiotherapy Plans with MU Objective Using Multiple Non Coplanar Arcs in Comparison with Conventional Dynamic Conformal Arc Technique. Med Phys 2012; 39:3855. [PMID: 28517549 DOI: 10.1118/1.4735738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Previous researches reported that RapidArc plans for stereotactic cranial radiotherapy have two to three times more MUs as compared to Conventional Dynamic Conformal Arc (DCA) Technique. This study aims to evaluate RapidArc plans using multiple non- coplanar arcs, developed with MU objective constraint in the optimization stage. METHODS Five single brain metastasis and three multiple metastases cases previously planned using DCA techniques in BrainLab iPlan Version 4.1 were investigated in this study. For each case, the target was defined on CT-MR fused images in iPlan. The CT images and contours of these patients were exported from iPlan to Varian Eclipse TPS Version 8.6. For each case, a DCA plan and a RapidArc plan with multiple non-coplanar arcs with and without using MU objective in the optimization stage were generated using Varian Trilogy machine with Millennium 120 MLC keeping the same prescription and critical structure dose limits. All plans were evaluated according to Conformity Index (CI-modified Paddick) Homogeneity Index (HI), and the normal tissue volume receiving various dose levels (V80%, V50%, V25% and V10%). RESULTS In all the plans, the target objectives were met and dose to OARs was within tolerance dose constraints. RapidArc plans with and without MU objective showed better CI and HI as supposed to DCA plans. V80%, V50%, V25% and V10% of normal tissue for RapidArc plans are equal or lesser than DCA plans. Single isocentre RapidArc plan for closely spaced multiple metastases cases showed better dose fall off between the lesions as supposed to DCA plans. RapidArc plans with MU objective resulted in comparable MUs as that of DCA plans. CONCLUSIONS Our study showed RapidArc plans done with and without MU objective have no significant dosimetric difference in plan objectives. Therefore, multiple non-coplanar RapidArc plans with MU objective is clinically feasible and can provide better treatment plans than conventional DCA plans, especially for complicated cases.
Collapse
Affiliation(s)
- J Mathew
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - S Paloor
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - M Riyas
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - S Divakar
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - G Perkins
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - R Hammoud
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - N Al-Hammadi
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| |
Collapse
|
48
|
Cohen L, Chandwani K, Raghuram N, Haddad R, Perkins G, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Nagendra H. OA10.02. Yoga for women with breast cancer undergoing radiotherapy (XRT): a randomized clinical trial with an active stretching control group. Altern Ther Health Med 2012. [PMCID: PMC3373721 DOI: 10.1186/1472-6882-12-s1-o38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
49
|
Mumcuoglu EU, Hassanpour R, Tasel SF, Perkins G, Martone ME, Gurcan MN. Computerized detection and segmentation of mitochondria on electron microscope images. J Microsc 2012; 246:248-65. [PMID: 22506967 DOI: 10.1111/j.1365-2818.2012.03614.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Mitochondrial function plays an important role in the regulation of cellular life and death, including disease states. Disturbance in mitochondrial function and distribution can be accompanied by significant morphological alterations. Electron microscopy tomography (EMT) is a powerful technique to study the 3D structure of mitochondria, but the automatic detection and segmentation of mitochondria in EMT volumes has been challenging due to the presence of subcellular structures and imaging artifacts. Therefore, the interpretation, measurement and analysis of mitochondrial distribution and features have been time consuming, and development of specialized software tools is very important for high-throughput analyses needed to expedite the myriad studies on cellular events. Typically, mitochondrial EMT volumes are segmented manually using special software tools. Automatic contour extraction on large images with multiple mitochondria and many other subcellular structures is still an unaddressed problem. The purpose of this work is to develop computer algorithms to detect and segment both fully and partially seen mitochondria on electron microscopy images. The detection method relies on mitochondria's approximately elliptical shape and double membrane boundary. Initial detection results are first refined using active contours. Then, our seed point selection method automatically selects reliable seed points along the contour, and segmentation is finalized by automatically incorporating a live-wire graph search algorithm between these seed points. In our evaluations on four images containing multiple mitochondria, 52 ellipses are detected among which 42 are true and 10 are false detections. After false ellipses are eliminated manually, 14 out of 15 fully seen mitochondria and 4 out of 7 partially seen mitochondria are successfully detected. When compared with the segmentation of a trained reader, 91% Dice similarity coefficient was achieved with an average 4.9 nm boundary error.
Collapse
Affiliation(s)
- E U Mumcuoglu
- Health Informatics Department, Informatics Institute, Middle East Technical University, Ankara 06800, Turkey.
| | | | | | | | | | | |
Collapse
|
50
|
AI Hammadi N, Perkins G, Rasul K, Wannenmacher M. Classic Kaposi's Sarcoma: A Case Report and Literature Review. Qatar Med J 2011. [DOI: 10.5339/qmj.2011.2.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Kaposi's Sarcoma (KS) is a rare multifocal spindle cell tumor with four epidemiologic variants: classic KS, African endemic KS, AIDS related KS, and immunosuppressant therapy related KS. Classic KS remains a rare but challenging disease because of its protracted, indolent course. The authors describe a case recently observed in our clinic, emphasizing the clinical management of the disease.
Collapse
Affiliation(s)
| | - G. Perkins
- **Medical Oncology, Hamad Medical Corporation, Doha, Qatar
| | - K. Rasul
- **Medical Oncology, Hamad Medical Corporation, Doha, Qatar
| | - M. Wannenmacher
- ***Department of Radiology, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|